IN THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application.

Please cancel claims 1-23 and 32-49 as follows.

LISTING OF THE CLAIMS

Claims 1-23 **(canceled)**

Claim 24 **(previously presented)** A humanized immunoglobulin having complementarity determining regions (CDRs) from a donor immunoglobulin and heavy and light chain variable region frameworks from human acceptor immunoglobulin heavy and light chains, which humanized immunoglobulin specifically binds to an antigen with an affinity constant of at least 10^8 M^{-1}, wherein said humanized immunoglobulin comprises amino acids from the donor immunoglobulin framework outside both the Kabat CDRs and the structural loop CDRs of the variable regions, wherein the donor amino acids replace corresponding amino acids in the acceptor immunoglobulin heavy or light chain frameworks, and each of said donor amino acids contributes to antigen binding as determined by X-ray crystallography.

Claim 25 **(previously presented)** A humanized immunoglobulin according to claim 24 which specifically binds to an antigen with an affinity in the range 10^8-10^{12} M^{-1}.

Claim 26 **(previously presented)** A humanized immunoglobulin according to claim 24, wherein the antigen is an IL-2 receptor.

Claim 27 **(previously presented)** A humanized immunoglobulin according to claim 24, wherein the donor immunoglobulin is the anti-CD4 T-cell receptor antibody.

Claim 28 **(previously presented)** A humanized immunoglobulin having complementarity determining regions (CDRs) from a donor immunoglobulin and heavy and light chain variable region frameworks from human acceptor immunoglobulin heavy and light chains, which humanized immunoglobulin specifically binds to an antigen with an effective antigen binding affinity, wherein said humanized immunoglobulin comprises amino acids from the donor immunoglobulin framework outside both the Kabat CDRs and the structural loop CDRs of the variable regions, wherein the donor amino acids replace corresponding amino acids in the acceptor immunoglobulin heavy or light chain frameworks, and each of said donor amino acids contributes to antigen binding as determined by X-ray crystallography.

Claim 29 **(previously presented)** A humanized immunoglobulin according to claim 28 which specifically binds to an antigen with a binding affinity similar to that of said donor immunoglobulin.

Claim 30 **(previously presented)** A humanized immunoglobulin according to claim 28, wherein the antigen is a human CD3 T-cell receptor.

Claim 31 **(previously presented)** A humanized immunoglobulin according to claim 28, wherein the donor immunoglobulin is the anti-CD3 T-cell receptor antibody.

Claims 32-49 **(canceled)**